Get the Stockscreener App
26.20
2.46%
-0.66
After Hours:
26.26
0.06
+0.23%
Acadia Pharmaceuticals Inc stock is traded at $26.20, with a volume of 1.08M.
It is down -2.46% in the last 24 hours and down -5.14% over the past month.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
See More
Previous Close:
$26.86
Open:
$26.82
24h Volume:
1.08M
Relative Volume:
0.75
Market Cap:
$4.43B
Revenue:
$890.53M
Net Income/Loss:
$30.57M
P/E Ratio:
145.56
EPS:
0.18
Net Cash Flow:
$80.53M
1W Performance:
-0.34%
1M Performance:
-5.14%
6M Performance:
+12.69%
1Y Performance:
+43.40%
1-Day Range:
$25.71
$27.22
1-Week Range:
$25.71
$27.81
52-Week Range:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Name
Acadia Pharmaceuticals Inc
Sector
Industry
Phone
858-558-2871
Address
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
26.20 | 4.54B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Citigroup | Buy |
| May-21-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Jan-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-10-24 | Resumed | Raymond James | Mkt Perform |
| Aug-07-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Mar-12-24 | Downgrade | Mizuho | Buy → Neutral |
| Mar-12-24 | Reiterated | Needham | Buy |
| Jan-30-24 | Initiated | Robert W. Baird | Outperform |
| Jan-24-24 | Upgrade | Needham | Hold → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-14-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-13-23 | Initiated | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-06-23 | Upgrade | Mizuho | Neutral → Buy |
| Oct-17-23 | Initiated | UBS | Buy |
| Oct-10-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-03-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-04-22 | Downgrade | Goldman | Neutral → Sell |
| Nov-01-22 | Initiated | Loop Capital | Hold |
| Aug-08-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Jun-21-22 | Downgrade | Jefferies | Buy → Underperform |
| Jun-16-22 | Upgrade | Jefferies | Hold → Buy |
| Mar-16-22 | Upgrade | Canaccord Genuity | Hold → Buy |
| Feb-09-22 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-05-22 | Upgrade | Citigroup | Neutral → Buy |
| Dec-21-21 | Downgrade | Guggenheim | Buy → Neutral |
| Nov-01-21 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-14-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-23-21 | Resumed | Needham | Hold |
| Jun-10-21 | Initiated | Berenberg | Hold |
| Apr-07-21 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Apr-06-21 | Downgrade | Canaccord Genuity | Buy → Hold |
| Apr-06-21 | Downgrade | Goldman | Buy → Neutral |
| Apr-06-21 | Downgrade | Jefferies | Buy → Hold |
| Apr-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-05-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Mar-10-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-09-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-09-21 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-09-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-09-21 | Downgrade | Raymond James | Strong Buy → Outperform |
| Mar-09-21 | Downgrade | Stifel | Buy → Hold |
| Dec-16-20 | Initiated | Mizuho | Buy |
| Nov-16-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Initiated | Morgan Stanley | Overweight |
| Jul-07-20 | Upgrade | Stifel | Hold → Buy |
| Apr-16-20 | Initiated | Jefferies | Buy |
| Mar-31-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-06-20 | Initiated | Citigroup | Buy |
| Dec-16-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Initiated | Oppenheimer | Perform |
| Oct-01-19 | Initiated | RBC Capital Mkts | Outperform |
| Sep-13-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-10-19 | Upgrade | Canaccord Genuity | Hold → Buy |
| Jul-23-19 | Reiterated | Needham | Buy |
| Dec-10-18 | Initiated | Canaccord Genuity | Hold |
| Sep-21-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-09-18 | Reiterated | Stifel | Hold |
| Aug-07-18 | Initiated | Stifel | Hold |
| Aug-06-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Acadia Pharmaceuticals Inc Stock (ACAD) Latest News
Revenue Check: Can ACADIA Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Volume & Verified Chart Pattern Trade Signals - baoquankhu1.vn
Institution Moves: Can ACADIA Pharmaceuticals Inc continue delivering strong returnsJuly 2025 Final Week & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Acadia Pharmaceuticals stock undervalued with $32 price target, says Canaccord By Investing.com - Investing.com India
Acadia Pharmaceuticals stock undervalued with $32 price target, says Canaccord - Investing.com Canada
ACAD: Analyst Sees Undervaluation with Promising Pipeline - GuruFocus
Weekly Earnings: Is Sun Country Airlines Holdings Inc a strong candidate for buy and hold2025 Trading Volume Trends & Safe Swing Trade Setups - baoquankhu1.vn
How do insiders feel about ACADIA Pharmaceuticals Inc.2025 Technical Patterns & Real-Time Volume Analysis - mfd.ru
Jobs Data: What is the target price for ACADIA Pharmaceuticals Inc stock2025 Market Outlook & Safe Entry Point Identification - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
RBC Capital Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $35 - 富途牛牛
H.C. Wainwright Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Maintains Target Price $37 - 富途资讯
Gains Recap: What is the target price for ACADIA Pharmaceuticals Inc stockQuarterly Profit Report & Free Community Consensus Stock Picks - baoquankhu1.vn
Discipline and Rules-Based Execution in ACAD Response - Stock Traders Daily
Campbell & CO Investment Adviser LLC Takes $838,000 Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Axecap Investments LLC Purchases New Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Assessing Acadia Pharmaceuticals (ACAD) Valuation After New Long Term Sales And Pipeline Targets - Sahm
Investing in ACADIA Pharmaceuticals (NASDAQ:ACAD) a Year Ago Would Have Delivered You a 51% Gain - 富途资讯
ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) Shows Strong Growth Momentum and Technical Setup - Chartmill
Is It Time To Reconsider ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness - Sahm
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Swings - Yahoo Finance
Is It Time To Reassess ACADIA Pharmaceuticals (ACAD) After Its Recent Share Price Surge - Yahoo Finance
Acadia projects $1.7 billion in 2028 sales for NUPLAZID and DAYBUE - Investing.com Nigeria
Neuren Pharmaceuticals flags DAYBUE global sales potential of US$700m by 2028 - Proactive financial news
Acadia Pharmaceuticals (ACAD) Projects Over $1B in 2025 Sales - GuruFocus
ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment - TipRanks
Acadia Pharma anticipates 2025 net sales to exceed $1 billion - StreetInsider
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf - MarketBeat
Acadia CEO Bands With Peers To Lobby Against MFN Drug Pricing for Small Biotech - BioSpace
ACADIA projects $1.7 billion in 2028 sales, launches new DAYBUE formulation - StreetInsider
Acadia Pharmaceuticals Provides Business And Pipeline Updates At 44Th Annual J.P. Morgan Healthcare Conference - TradingView
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Lobbying Update: $30,000 of ACADIA PHARMACEUTICALS lobbying was just disclosed - Quiver Quantitative
Published on: 2026-01-13 01:54:16 - Улправда
Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience - marketscreener.com
Watch Acadia Pharmaceuticals Focuses on Next-Gen Neuroscience - Bloomberg
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Wall Street Zen Upgrades ACADIA Pharmaceuticals (NASDAQ:ACAD) to "Buy" - MarketBeat
Behavioral Patterns of ACAD and Institutional Flows - Stock Traders Daily
ACAD Q3 Earnings Beat, Nuplazid & Daybue Drive Y/Y Revenue Growth - MSN
Can ACADIA Pharmaceuticals Inc. stock attract ESG capital inflows2025 Analyst Calls & Growth Focused Stock Pick Reports - ulpravda.ru
How ACADIA Pharmaceuticals Inc. stock compares to industry benchmarks2025 Market Outlook & AI Driven Stock Reports - Улправда
Acadia drops development of carbetocin in PWS - The Pharma Letter
Pullback Watch: Will ACADIA Pharmaceuticals Inc. stock outperform international peersJuly 2025 Review & Fast Gain Stock Trading Tips - ulpravda.ru
Will ACADIA Pharmaceuticals Inc. stock beat EPS estimatesProduct Launch & Risk Adjusted Swing Trade Ideas - ulpravda.ru
Will ACADIA Pharmaceuticals Inc. stock see PE expansionTrade Performance Summary & Reliable Price Breakout Signals - Улправда
Is ACADIA Pharmaceuticals Inc. stock a defensive play in 2025Forecast Cut & Free Reliable Trade Execution Plans - Улправда
Stock Market Recap: Will ACADIA Pharmaceuticals Inc. stock outperform international peersJuly 2025 Drop Watch & AI Powered Buy and Sell Recommendations - ulpravda.ru
Why ACADIA Pharmaceuticals Inc. (ACAD) Skyrocketed on Friday - MSN
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Momentum - Sahm
ACADIA Pharmaceuticals (ACAD) Sees Target Price Raised by Citigr - GuruFocus
UBS Raises Price Target to $40 for ACADIA Pharmaceuticals (ACAD) - GuruFocus
Acadia Pharmaceuticals Inc Stock (ACAD) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):